Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c
Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16).
As of September 30, 2017, Regulus had cash, cash equivalents and short-term investments of $71.4 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.